Insider Buying: Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) President Purchases 1,400 Shares of Stock

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) President Amir F. Heshmatpour acquired 1,400 shares of the stock in a transaction dated Monday, May 12th. The stock was purchased at an average cost of $7.23 per share, with a total value of $10,122.00. Following the purchase, the president now directly owns 1,753,000 shares of the company’s stock, valued at $12,674,190. This trade represents a 0.08% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Neonc Technologies Trading Down 0.8%

NASDAQ:NTHI traded down $0.06 during mid-day trading on Monday, hitting $7.43. 62,188 shares of the company’s stock were exchanged, compared to its average volume of 85,148. Neonc Technologies Holdings, Inc. has a fifty-two week low of $4.11 and a fifty-two week high of $25.00.

Neonc Technologies (NASDAQ:NTHI) last released its quarterly earnings results on Friday, May 9th. The company reported ($2.10) earnings per share (EPS) for the quarter. The firm had revenue of $0.04 million for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Neonc Technologies stock. HighPoint Advisor Group LLC purchased a new stake in Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 21,672 shares of the company’s stock, valued at approximately $290,000.

About Neonc Technologies

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing.